DataM resources that are widely useful for your reference. We have curated special links for you to browse through

The rapid growth of AI infrastructure is transforming power distribution inside U.S. data center white spaces. As rack power requirements move from conventional enterprise levels toward 120 kW and beyond 200 kW, electrical suppliers face increasing demand for high-amperage track busway, tap-off systems, connectors, cable pathways and advanced power distribution architectures.
November 13, 2026

The expansion of AI data centers, grid modernization and industrial electrification is increasing pressure on the U.S. transformer supply chain. However, expanding transformer assembly capacity does not automatically resolve upstream material constraints. Grain-oriented electrical steel (GOES), a critical material for transformer cores, remains concentrated among a single domestic producer, Cleveland-Cliffs, while imported GOES, laminations and cores continue to supplement U.S. manufacturing.
November 13, 2026

U.S. distribution grids are facing growing pressure from EV charging, electrified buildings, commercial development and rising electricity demand. Extended transformer lead times and critical grid equipment shortages are forcing utilities to explore alternatives to conventional infrastructure expansion. Virtual power plants (VPPs), distributed energy resources (DERs), managed EV charging, smart thermostats and battery storage are emerging as tools to reduce peak demand, improve asset utilization and defer selected grid upgrades.
November 13, 2026

Retatrutide is generating significant commercial attention before regulatory approval, with illegal online sellers, counterfeit products and unapproved peptide markets creating a complex pharmaceutical commercialization environment. This article examines how the pre-approval retatrutide black market could influence future drug launch strategies, patient expectations, pricing perceptions, brand protection and market access.
November 12, 2026

Biotech funding is rising in 2026, but startup survival remains increasingly difficult. Despite $12.6 billion in biopharma venture capital funding during H1 2026, healthcare financing deal counts have declined, with capital concentrating in fewer companies.
November 12, 2026

Keytruda's approaching U.S. patent cliff is creating one of the most significant biosimilar commercialization opportunities in oncology. With Formycon and Zydus advancing FYB206 through FDA review, the competitive landscape is shifting from regulatory development toward market access, institutional contracting and provider adoption.
November 12, 2026